Table 7.
Comparison of biopsy and final surgical histology of index lesions
| Pathology | Biopsy, N = 182 (%) | Final surgical patients, N = 182 (%) |
|---|---|---|
| Invasive carcinoma | 141 (77.5) | 137 (75.3) |
| IDC | 89 (48.9) | 56 (30.8) |
| IDC+DCIS | 21 (11.6) | 53 (29.1) |
| ILC | – | 20 (11.0) |
| IDC+ILC | 4 (2.2) | 1 (0.5) |
| ILC, DCIS | – | 2 (1.1) |
| ILC+DCIS | 1 (0.5) | – |
| IDC+ILC+DCIS | – | 1 (0.5) |
| ITLC | – | 3 (1.7) |
| ILC/ITLC | 22 (12.1) | – |
| IMPC | – | 1 (0.5) |
| Breast cancer (unknown type) | 3 (1.7) | – |
| Papillary cancer | 1 (0.5) | – |
| In situ carcinoma | 41 (22.5) | 30 (16.5) |
| DCIS | 38 (20.8) | 28 (15.4) |
| DCIS+Paget’s disease | – | 2 (1.1) |
| Paget’s disease | 3 (1.7) | – |
| High risk | – | 4 (2.2) |
| ADH/ALH/LCIS | 4 (2.2) | |
| Benign pathology | – | 11 (6.0) |
| Fat necrosis | – | 4 (2.2) |
| Inflammation (biopsy site) | – | 6 (3.3) |
| FCC | 1 (0.5) |
IDC invasive/infiltrating ductal carcinoma, DCIS ductal carcinoma in situ, ILC invasive lobular carcinoma, ITLC invasive tubulolobular carcinoma, ADH atypical ductal hyperplasia, LCIS lobular carcinoma in situ, ALH atypical lobular hyperplasia, IMPC invasive micropapillary carcinoma, FCC fibrocystic change, – not assessed